產(chǎn)品搜索
相關(guān)文章
- 選擇性組蛋白去乙?;敢种苿┰谀[瘤免疫治療中的作用及前景
- 【論文作者回應(yīng)】小蘇打“餓死”腫瘤?教授為你答疑解惑
- 降糖&減肥明星靶點:GLP1R/GIPR/GCGR
- 剛收到的細(xì)胞株如何進(jìn)行合理的處理?
- ATCC細(xì)胞株的特殊性質(zhì)或標(biāo)志必須在整個培養(yǎng)期間始終存在
- AVβ6靶點細(xì)胞篩選模型
- IgE:過敏與免疫的“雙面分子”
- 從諾輝財報看甲基化市場,科佰生物助力甲基化標(biāo)準(zhǔn)品的開發(fā)
- 上海細(xì)胞中心分享細(xì)胞分裂后的三種情況
- 【產(chǎn)品推介】LAG-3靶點細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73287BCR-ABL1 Y253H/BaF3激酶細(xì)胞株

- 詳細(xì)內(nèi)容
CBP73287 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [Y253H]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1. WB of BCR-ABL1 [Y253H]/BaF3 | |
2.Sanger of BCR-ABL1 [Y253H]/BaF3 Figure 2. BCR-ABL1 Y253H Figure 3. BCR-ABL1 [Y253H]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 Y253H Cells (C1). | |